Author: aveak

Reunion Neuroscience Partners with Seleni Institute on Effective Diagnosis and Treatment of Maternal Mental Health Disorders

Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic therapeutic solutions, today announced a new partnership with the Seleni Institute, a New York City based nonprofit that provides treatment and training regarding maternal mental health and...

09 October, 2024

Reunion Neuroscience Appoints Mark Pollack, M.D., as Chief Medical Officer

Reunion Neuroscience Inc. today announced the appointment of Mark Pollack, M.D., as Chief Medical Officer. Dr. Pollack previously served as a member of Reunion’s Advisory Board and is a highly accomplished psychiatrist with decades of leadership experience in neuroscience-focused drug development and clinical research. Pollack replaces Dr. Robert Alexander who...

10 September, 2024

Reunion Neuroscience Joins the Is Mom OK? Initiative Recognizing Maternal Suicide Prevention Month

Reunion Neuroscience Inc. today announced its sponsorship of “Is Mom Ok?” in recognition of Maternal Suicide Prevention Month. This unprecedented initiative, launched by Cherished Mom, a renowned nonprofit organization dedicated to transforming the landscape of maternal mental health, is aimed at providing essential support and resources for pregnant and postpartum...

04 September, 2024

Reunion Neuroscience Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression

Reunion Neuroscience Inc. today announced that the first patient has been dosed in the RECONNECT Phase 2 clinical trial of RE104 for the treatment of postpartum depression (PPD). RE104 was designed to be a safe, fast-acting, single-dose therapy to benefit patients suffering from underserved mental health disorders, including PPD....

23 July, 2024

Reunion Neuroscience Announces Publication of Results from Early Preclinical Studies Demonstrating the Potential of RE104 for Development in Depressive Disorders

Reunion Neuroscience Inc., today announced the publication of the results of preclinical studies in ACS Chemical Neuroscience that validate the decisions to pursue RE104, a proprietary, patented prodrug of 4-OH-DiPT as a potential therapeutic in depressive disorders....

20 May, 2024

Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings

Reunion Neuroscience Inc. today announced the close of a $103 million Series A financing co-led by MPM BioImpact and Novo Holdings, with participation from Arkin Bio Capital, Mitsui & Co. Global Investment, Plaisance Capital, FemHealth Ventures, and Palo Santo....

02 May, 2024

Fluence and Reunion Neuroscience Inc. Announce Partnership on Phase 2 Clinical Study of RE104 for Postpartum Depression

Fluence a global leader in education, training, and certification for practitioners of psychedelic medicine and Reunion Neuroscience today announced a strategic partnership to support the Phase 2 clinical study evaluating the safety and efficacy of RE104 in postpartum depression (PPD)...

15 April, 2024

Reunion Neuroscience Inc. Announces Upcoming Presentations at the Anxiety and Depression Association of America (ADAA) 2024 Conference

Reunion Neuroscience today announced that the clinical dataset from the Company’s Phase 1 study of its lead asset, RE104, will be presented in both a podium and poster at the Anxiety and Depression Association of America (ADAA) Conference taking place April 11-14, 2024, in Boston, MA....

03 April, 2024

Reunion Neuroscience Inc. to Participate in October Investor Conferences

WILMINGTON, October 5, 2023 – Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today announced that Greg Mayes, Chief Executive Officer, will participate in the following investor conferences. Please contact your representative to schedule a 1x1...

05 October, 2023

Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate a Phase 2 Study of RE104 for the Treatment of Postpartum Depression

WILMINGTON, September 18, 2023 – Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 2 study of...

18 September, 2023